- Home
- AURA vs ESPR Comparison
AURA vs ESPR Comparison
Compare AURA & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AURA
- ESPR
- Stock Information
- Founded
- AURA 2007
- ESPR 2008
- Country
- AURA United States
- ESPR United States
- Employees
- AURA N/A
- ESPR N/A
- Industry
- AURA Biotechnology: Pharmaceutical Preparations
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- AURA Health Care
- ESPR Health Care
- Exchange
- AURA Nasdaq
- ESPR Nasdaq
- Market Cap
- AURA 370.1M
- ESPR 305.0M
- IPO Year
- AURA 2021
- ESPR 2013
- Fundamental
- Price
- AURA $5.36
- ESPR $0.95
- Analyst Decision
- AURA Strong Buy
- ESPR Buy
- Analyst Count
- AURA 4
- ESPR 7
- Target Price
- AURA $22.75
- ESPR $6.07
- AVG Volume (30 Days)
- AURA 482.7K
- ESPR 5.5M
- Earning Date
- AURA 05-08-2025
- ESPR 05-06-2025
- Dividend Yield
- AURA N/A
- ESPR N/A
- EPS Growth
- AURA N/A
- ESPR N/A
- EPS
- AURA N/A
- ESPR N/A
- Revenue
- AURA N/A
- ESPR $332,314,000.00
- Revenue This Year
- AURA N/A
- ESPR $5.17
- Revenue Next Year
- AURA N/A
- ESPR N/A
- P/E Ratio
- AURA N/A
- ESPR N/A
- Revenue Growth
- AURA N/A
- ESPR 185.66
- 52 Week Low
- AURA $4.84
- ESPR $0.93
- 52 Week High
- AURA $12.38
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- AURA 37.19
- ESPR 22.73
- Support Level
- AURA $4.84
- ESPR $0.93
- Resistance Level
- AURA $5.82
- ESPR $1.06
- Average True Range (ATR)
- AURA 0.48
- ESPR 0.09
- MACD
- AURA 0.03
- ESPR -0.02
- Stochastic Oscillator
- AURA 32.20
- ESPR 3.57
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.